======================================================================
EXPERIMENTAL VALIDATION CHECKLIST
Leigh Syndrome Biomarker Candidates
======================================================================

PHASE 2: FUNCTIONAL VALIDATION
----------------------------------------------------------------------

A. Mitochondrial Function Assays
   □ Complex I activity assay
   □ Complex II activity assay
   □ Complex IV (COX) activity assay
   □ Complex V (ATP synthase) activity assay
   □ Citrate synthase activity (normalization)

B. Cellular Bioenergetics
   □ ATP production assay (luminescence-based)
   □ Oxygen consumption rate (Seahorse/Oroboros)
   □ Mitochondrial membrane potential (TMRE/JC-1)
   □ ROS production (MitoSOX)

C. Cell/Tissue Models
   □ Patient-derived fibroblasts (if available)
   □ Patient muscle biopsies (archived)
   □ Induced pluripotent stem cells (iPSCs)
   □ Neuronal differentiation from iPSCs

PHASE 3: CLINICAL BIOMARKER VALIDATION
----------------------------------------------------------------------

A. Sample Requirements
   Patient cohort:
   □ Leigh syndrome patients (n≥20)
   □ Age-matched controls (n≥20)
   □ Other mitochondrial disease controls (n≥10)

   Sample types:
   □ Plasma/serum (biomarker detection)
   □ Muscle biopsy (respiratory chain analysis)
   □ CSF (neurological biomarkers)

B. Biomarker Measurements
   □ ELISA development for top 5 candidates
   □ Multi-plex immunoassay (Luminex)
   □ Mass spectrometry validation

SAMPLE PREPARATION PROTOCOLS
----------------------------------------------------------------------

For Western Blot:
  □ Protein extraction (RIPA or mitochondrial isolation)
  □ BCA/Bradford protein quantification
  □ SDS-PAGE (4-12% gradient gels)
  □ PVDF membrane transfer
  □ Blocking (5% milk or BSA)
  □ Primary antibody (1:1000, overnight 4°C)
  □ Secondary antibody (1:5000, 1h RT)
  □ ECL detection
  □ Densitometry analysis (ImageJ)

For qPCR:
  □ RNA extraction (TRIzol or RNeasy)
  □ RNA quality check (260/280 ratio ≥1.8)
  □ DNase treatment
  □ cDNA synthesis (1-2 μg RNA)
  □ qPCR (SYBR Green or TaqMan)
  □ ΔΔCt analysis (normalized to housekeeping)

STATISTICAL CONSIDERATIONS
----------------------------------------------------------------------

Sample Size Calculation:
  □ Power analysis (α=0.05, β=0.2, effect size from proteomics)
  □ Minimum n=20 per group recommended

Statistical Tests:
  □ Normality test (Shapiro-Wilk)
  □ T-test or Mann-Whitney U (depending on distribution)
  □ Multiple testing correction (Bonferroni or FDR)
  □ ROC curve analysis (diagnostic potential)

ESTIMATED BUDGET (USD)
----------------------------------------------------------------------
  Western Blot (10 targets):
    - Antibodies: $3,000-5,000
    - Reagents: $500-1,000

  qPCR (12 targets):
    - Primers: $300-600
    - Master mix: $500-800

  Functional Assays:
    - Complex activity kits: $2,000-3,000
    - ATP assay: $500-800
    - Seahorse XF analysis: $3,000-5,000

  Total Estimated Cost: $10,000-15,000

======================================================================
END OF VALIDATION CHECKLIST
======================================================================